SynthesisFrontiers in cellular and infection microbiology2025
Gut microbiome dysbiosis in chronic lung disease: a systematic review and meta-analysis.
Synthesis in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global research status and development trends of chronic obstructive pulmonary disease and gut microbiota: a comprehensive analysis based on bibliometrics and knowledge visualization.Frontiers in microbiology · 2026Pooled it
- Global research trends and thematic evolution of respiratory microbiota in COPD: a bibliometric study.Frontiers in medicine · 2026Pooled it
- Axial Connectivity of the Lung Microbiome: A Review of Interorgan Crosstalk.Comprehensive physiology · 2026Review
- Exercise-induced gut microbiota metabolites and the gut-lung axis: implications for chronic obstructive pulmonary disease.Journal of thoracic disease · 2026Review
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Recent data suggest that the gut-lung axis plays a role in the development of lung disease. However, the potential association between the gut microbiota and chronic lung disease (CLD) remains unclear. This study aimed to investigate changes in the gut microbiome in patients with CLD. Methods: We searched PubMed, Web of Science, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang, and VIPC databases from inception to August 1, 2024. The inclusion criteria involved studies that reported on gut flora in patients with CLD. Two independent reviewers used standardized methods to search, screen, and code included studies. Publication bias was analyzed using Egger's test. Changes in the gut microbiome were assessed through α-diversity, β-diversity, and changes/differences in relative abundance, and results were evaluated using a random-effects model. Results: A total of 27 studies were included: 21 on chronic obstructive pulmonary disease (COPD; 1,273 patients and 6,718 healthy controls [HCs]), six on asthma (559 patients and 5,310 HCs), one on COPD and asthma combined, and one on pulmonary cystic fibrosis. Compared with HCs, α-diversity was decreased in patients with COPD (Shannon index: standard mean difference [SMD] = -0.38; 95% confidence interval [CI], -0.76 to 0.00, Conclusion: The gut microbiota of patients with COPD is imbalanced, and the abundance of probiotics is lower than in healthy individuals. Further exploration of the potential role of probiotics in COPD may provide promising targets for treatment. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022378296.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.